SMPDL3B and focal segmental glomerulosclerosis: Another example is the direct action of rituximab on sphingomyelin-phosphodiesterase-acid-like-3b (SMPDL-3b) expression in podocytes, whose upregulation by rituximab can prevent disruption of the actin cytoskeleton in response to FSGS sera [18].